Navigation Links
London Genetics and Astrimmune to Collaborate on Cancer Vaccine
Date:11/12/2010

une, said, 'Pancreatic cancer is an area of serious unmet medical need, with a five-year survival rate of around 5% and few treatment options. Availability of a biomarker to select those patients mostly likely to benefit from Astrimmune's vaccine candidate can be expected to expedite the development of this product and increase its chances of coming to market in the future. London Genetics is an expert in this area and Astrimmune is delighted to be working with the company on this important part of the project development.'

About London Genetics: London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise, based on its access to 3,000 academic groups with a GBP650m annual research spend. Recent deals by London Genetics include a partnership with Diaceutics to accelerate biomarker development in the biopharmaceutical industry. LGL is based in central London and has ISO 9001 accreditation. For further information, please go to http://www.londongenetics.com

About Astrimmune: Astrimmune (Company Registration: 06379008), is a limited, social enterprise company developing treatments for gastrointestinal cancers. Astrimmune is focussed on the elimination of cancer growth factors that are not yet commercialised and is progressing a new immunogen vaccine candidate for use in gastro-intestinal cancers. The distillation of their prior knowledge, coupled with a research progr
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
2. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. First Awards Made by London Genetics Proof-of-Concept Fund
5. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
6. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
7. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
8. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
9. Interleukin Genetics Reports Third Quarter 2010 Financial Results
10. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
11. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... CITY, Md., Oct. 11, 2011 Christine K. Pierre, ... a "Professional Woman of the Year" by the National ... recognizes Pierre,s "outstanding leadership and commitment" within her profession, ... women. Pierre founded RxTrials, Inc., in 1994, ...
... Johnson (NYSE: JNJ ) will host a conference ... Tuesday, October 18, 2011, to review third-quarter results.  Dominic Caruso, ... Vice President, Investor Relations, will host the call. ... visiting the Company,s website at www.investor.jnj.com . ...
Cached Medicine Technology:Christine Pierre Selected as "Professional Woman of the Year" 2
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Scientists who used ... laboratory say their breakthrough could provide a new way ... stomach diseases. The team used human pluripotent stem ... in the body -- to grow the functional miniature ... bacteria, a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... during and after treatment resulted in less fatigue, greater ... - Exercise during and after treatment improves quality of ... or prostate cancer, a new study finds. , "Using ... potential to benefit patients both physically and psychologically, as ...
... ... 7,000 stores in under five months of operation. The site offers 30,000 coupons from 7,000 ... 500 votes per day, making it one of the fastest growing coupons/deals sites ever. ... (PRWEB) May 27, 2010 ...
... , THURSDAY, May 27 (HealthDay News) -- A new ... that many people don,t know enough about sun damage ... survey showed that despite our repeated warnings about the ... sun protection, many people could not correctly answer true/false ...
... ... and published by Random House Mondadori this ,practical guide teaches Latina women how to ... ... Guía Para Vestir Mejor (Discover Your Style: Your Guide to Dressing Better) written ...
... "color-coded" laboratory mice are providing researchers with a novel ... monitor the cellular immune responses of transplanted tissue in ... the June issue of Nature Medicine , which ... a key consideration in developing strategies to improve transplant ...
... at the UCLA Medical Center found that antiviral therapy ... is the most cost-effective approach to treating patients with ... Full details appear in the June issue of ... behalf of the American Association for the Study of ...
Cached Medicine News:Health News:Exercise Boosts Health of Cancer Patients 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Many People Still Don't Know How to Protect Against Skin Cancer 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 3Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
Medicine Products: